Get notified of page updates

People with advanced or metastatic colorectal, endometrial, ovarian, stomach, esophageal or other cancers

Clinicaltrials.gov identifier:
NCT05572684

Study Contact Information:

 

 

PRINTER FRIENDLY PAGE

Study of a New Immunotherapy Treatment Called NC410 in People with Different Types of Advanced or Metastatic Cancers

People with advanced or metastatic colorectal, endometrial, ovarian, stomach, esophageal or other cancers

Clinicaltrials.gov identifier:
NCT05572684

Study Contact Information:

 

 

PRINTER FRIENDLY PAGE
Overview
Who Can Join
Contact
Glossary on
off

About the Study

NOTE: This study is no longer recruiting people. 

 

This study will test the safety and effectiveness of a new drug called NC410 used in combination with the agent Keytruda (pembrolizumab) in people with advanced or cancers that cannot be removed by surgery. The study is open to people with colorectal, endometrial, ovarian, stomach, esophageal, head and neck and other cancers that:

  • have a tumor marker known as microsatellite stable (MSS), OR
  • have been treated with and no longer respond to treatment with  drugs known as immune checkpoint inhibitors.

 

This Study is Open To:

NOTE: This study is no longer recruiting people. 

This Study is NOT Open To:

NOTE: This study is no longer recruiting people. 

Study Contact Information: